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Summary The purpose of the study was to evaluate the incidence, riskfactors and changes in severity with time of cisplatin nephrotoxicity in
children. A total of 35 children underwent measurement of glomerular filtration rate (GFR) and tubular function after completion of cisplatin
chemotherapy. No child received ifosfamide. A clinically relevant 'nephrotoxicity score' was derived from GFR and serum magnesium. Follow-
up studies were performed in 16 children at 1 year and in 15 at 2 years after cisplatin. Considerable interpatient variability in nephrotoxicity
was observed. Treatment was modified in three patients because of nephrotoxicity. GFR was low in 18 out of 31 patients. Proximal nephron
toxicity caused hypomagnesaemia in ten patients and hypocalcaemia in five patients. Elevated urinary N-acetylglucosaminidase excretion
was seen in 22 out of 30 children, indicating subclinical tubular toxicity. Nephrotoxicity was less severe in children who received cisplatin
courses at a dose rate of 40 mg m-2 dar' than in those who received higher dose rates (P < 0.005), but there was no correlation with total
dose received. Follow-up studies revealed partial recovery of GFR (P < 0.05). Glomerular and proximal nephron toxicity are common in
children treated with cisplatin, and more severe at higher dose rates. Despite partial recovery of GFR, the long-term outcome of nephrotoxicity
remains unknown and careful monitoring of chronic toxicity is necessary.
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The use of combination chemotherapy has led to dramatic
improvements in the survival rates from many childhood malig-
nancies during the last three decades. However, cytotoxic drugs
may also cause severe and chronic side-effects, leading to perma-
nent ill-health, disability or even premature death (Morris Jones
and Craft, 1990). The development of effective strategies to
prevent these adverse events depends on careful evaluation of
toxicity both during and after treatment.
In view of its established efficacy, cisplatin has retained an
important role in the treatment ofseveral childhood solid tumours,
including neuroblastoma, osteosarcoma, hepatic and brain
tumours, despite the increasing use of its apparently less nephro-
toxic analogue carboplatin. Indeed, recent evidence has suggested
that cisplatin may be more active than carboplatin in some germ
cell tumours in adolescents and adults (Bajorin et al, 1993).
However, even with the use ofhyperhydration and otherprotective
measures, nephrotoxicity is still a common and potentially serious
adverse effect of cisplatin in both adults (Madias and Harrington,
1978; Schilsky et al, 1982; Daugaard and Abildgaard, 1989) and
children (Womer et al, 1985; Brock et al, 1991). Despite numerous
publications concerning cisplatin nephrotoxicity in adults, there is
less information and no clear consensus on the importance of
patient- and treatment-related risk factors for the development of
nephrotoxicity in children. Furthermore, as there are few data
concerning the long-term outcome of cisplatin nephrotoxicity in
children (Brock et al, 1991), especially that of tubular toxicity,
concern persists over the possibility that significant chronic renal
damage may become evident only in adult life.
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Therefore, this study was designed to investigate these issues.
The aims were to evaluate first, the incidence, nature and severity
of glomerular and renal tubular toxicity in children treated with
cisplatin; second, the relevance of patient- and treatment-related
risk factors in the development of such toxicity; and finally, the
changes in renal function with time after completion ofcisplatin.
METHODS
Patients and treatment
Between August 1988 and August 1991, 35 children and adoles-
cents resident in the Northern Health Region of England received
cisplatin chemotherapy and were followed up aftertreatment at the
Regional Paediatric Oncology Unit in Newcastle upon Tyne. No
child died from cisplatin nephrotoxicity. The mean age at diag-
nosis was 5.7 (range 0.6-17.8) years. A total of 16 children had
neuroblastoma, seven had a brain tumour, five each had osteosar-
coma or had a germ cell tumour, and two had a hepatic tumour. At
diagnosis, all children had a normal serum creatinine concentra-
tion. Glomerular filtration rate (GFR) was measured from the
plasma clearance of 5'Cr-labelled ethylenediaminetetraacetic acid
([5tCr]EDTA) before cisplatin treatment in 30 children, and was
normal (.87 ml min-' 1.73 m-2) in 28 but slightly reduced in the
other two. One child with partial urinary tract obstruction at diag-
nosis due to tumour had a GFR of72 ml min-' 1.73 m-2. The other
child had a marginally low GFR of 81 ml min-' 1.73 m-2 at
diagnosis, without obvious cause. All children had normal renal
tubular function as defined by normal serum electrolyte, calcium
and magnesium concentrations, and normal urinalysis. No child
had renal invasion by tumour nor urinary tract obstruction. The
study protocol received local institutional ethics committee
approval. Informed verbal consent was obtained from the patients
and/or parents.
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After completion ofchemotherapy, all 35 patients underwent an
initial 'baseline' study at a median of 1 (1-21) month after the last
cisplatin treatment (within 3 months in 23 patients). During the
study period (i.e. August 1988-91), all patients surviving to 1 or 2
years after completion ofcisplatin were restudied. A total of 16 of
the 35 children underwent a '1-year post-treatment' study (1-year
study) at a median of 14 (11-19) months post-cisplatin, and 15 a
'2-year post-treatment' study (2-year study) at a median of 25
(20-31) months post-cisplatin. The 1-year study was performed at
a median of 11 (range 4-14) months, and the 2-year study 20
(range 7-27) months after the baseline study.
The mean total dose of cisplatin received was 568 (291-750)
mg m-2, given over a mean of5.0 (2-8) courses. Several schedules
of cisplatin were used, all using intravenous hydration at 3 1 m-2
day-'. The cisplatin dose per course ranged from 60 to 200 mg m-2,
given as a continuous infusion (40-100 mg m-2 day-') over 1-5
days, except in the children with germ cell tumours (20-min infu-
sion). All high dose (200 mg m-2) cisplatin courses were given
over 5 days (i.e. 40 mg m-2 day-'). The treatment protocols were
divided into two groups according to the rate at which cisplatin
was delivered during each treatment course (i.e. cisplatin dose
rate). Those protocols for neuroblastoma and brain tumours were
characterized by a 'low' cisplatin dose rate (40 mg m-2 day-',
n = 23), and those for osteosarcoma, germ cell or hepatic tumours
by a 'high' dose rate [>40-120 mg m-2 (mean 96.3, standard error
4.3), n = 12]. Treatment courses were repeated every 3 weeks,
except in children with neuroblastoma who received a rapid sched-
uling protocol with courses of 80 and 200 mg m-2 at 10-20 day
intervals.
Other chemotherapy included actinomycin D, bleomycin, carbo-
platin, cyclophosphamide, doxorubicin, etoposide, melphalan and
vincristine. The carboplatin (1 g m-2) and melphalan (180 mg m-2)
were given in single doses as part of high-dose chemotherapy
before autologous bone marrow transplantation in seven children
with neuroblastoma. No child received ifosfamide or radio-
therapy to a treatment field that included the kidneys. Potentially
nephrotoxic supportive treatment (intravenous aminoglycosides,
vancomycin, acyclovir or amphotericin B) was given to 28 of
the children for between 6 and 154 days (mean 35.3 days for
whole group).
Investigations
The clinical consequences of nephrotoxicity were recorded, in
particular tetany. Renal function was assessed using a standardized
protocol (Skinner et al, 1991).
Glomerular function
Serum creatinine concentration and GFR (using the [5'Cr]EDTA
plasma clearance method) were measured.
Proximal nephron function
Concentrations of electrolytes, creatinine, calcium, magnesium,
phosphate and glucose were measured in corresponding blood and
urine samples, with calculation of the fractional excretions of
sodium, potassium, calcium, magnesium, phosphate and glucose,
and of the renal tubular threshold for phosphate (Tmp/GFR)
(Skinner et al, 1991). The fractional excretion ofa substance is the
percentage of the filtered load at the glomerulus that is subse-
quently excreted in the urine; an abnormally high fractional
excretion indicates reduced tubular reabsorption. The majority of
reabsorption of the above molecules occurs in the proximal
nephron. Except with glucose, a fractional excretion was consid-
ered abnormal only when it was elevated in the presence of a
reduced blood concentration. TheTmp/GFR provides a measure of
tubular phosphate reabsorption, being reduced in the presence of
impaired reabsorption.
In addition, the urine excretion of a low-molecular-weight
protein, either 32-microglobulin (52-M) or retinol-binding protein
(RBP), was measured and expressed as a ratio to the urine creati-
nine concentration in the same sample. Increased urine excretion
indicates reduced proximal nephron reabsorption.
Distal nephron function
Serum bicarbonate concentration and early morning urine pH were
measured to evaluate both proximal and distal nephron regulation
of acid-base balance. Early morning urine osmolality was deter-
mined as a measure of urinary concentration. Although impaired
urinary concentration may result from either proximal or distal
nephron dysfunction, severe impairment is more likely to be
observed in distal nephron toxicity (Skinner et al, 1991).
General aspects ofrenal function
The urinary concentrations of two renal tubular enzymes [alanine
aminopeptidase (AAP) and N-acetylglucosaminidase (NAG)] and
oftotal protein were measured and expressed as ratios to the urine
creatinine concentration. Increased urine excretion of AAP and
NAG implies tubular damage. Blood pressure was also measured.
Nephrotoxicity grading
Nephrotoxicity grading was performed using a system that grades
(on a 0-4 scale) GFR and serum magnesium concentration, with
summation to give a 'nephrotoxicity score', potentially ranging
from 0 to 8, based on the common clinically relevant aspects of
cisplatin nephrotoxicity (Table 1).
Reference ranges (Table 2)
Reference ranges for serum biochemistry and fractional excretions
were obtained from investigation of 105 otherwise healthy children
and adolescents (aged 0.1-16.6 years, 27 male children) attending
hospital for investigation ofaproven urinary tract infection (treated
at least I month previously), in whom clinical examination, renal
and urinary tract investigations and imaging proved to be normal.
Age-related reference ranges for RBP, pH, osmolality, AAP and
NAG were derived from early-morning urine samples in 322
normal schoolchildren and students (aged 3.9-18.7 years, 170 male
patients) with no personal or family history of renal disease.
Previously outlined reference ranges (Skinner et al, 1991) were
used for GFR, 02-M, and age- or sex-dependent biochemical
variables (serum creatinine, bicarbonate and magnesium).
Statistical analysis
Multiple linear regression analysis was used to evaluate age at
start of treatment, total cisplatin dose, cisplatin dose rate, time
since completion of cisplatin (in months), sex and duration (in
days) of other potentially nephrotoxic drugs as predictors for clin-
ically relevant nephrotoxicity measured by GFR, serum magne-
sium, fractional excretion ofmagnesium and nephrotoxicity score.
Initially, all predictor variables were included simultaneously in
multiple regression to determine which had a significant influence
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Table 1 Grading of cisplatin nephrotoxicity in children
Nephrotoxicity grade GFR Mg
<2 years .2 years
0 .90 .0.75 >0.70
1 60-89 0.60-0.74 0.55-0.69
2 40-59 0.50-0.59 0.45-0.54
3 20-39 No symptoms, but
0.40-0.49 0.35-0.44
4 <20 Tetany or convulsion or
<0.40 <0.35
Total score (N,) (i.e. sum of GFR + Mg)
0 No nephrotoxicity
1 Mild nephrotoxicity
2-3 Moderate nephrotoxicity
.4 Severe nephrotoxicity
GFR, glomerular filtration rate (ml min-' 1.73 m-2); Mg, serum magnesium
concentration (mmol 1-1). Tetany is defined by clinical symptoms/signs
(carpopedal spasm, Chvostek's sign, Trousseau's sign) with biochemistry
(moderate or severe hypomagnesaemia - <0.60 at <2 years of age, <0.55 at
>2 years). Hypocalcaemia may also cause tetany. If hypomagnesaemia and
hypocalcaemia co-exist in the presence of tetany, assume that hypomagnesaemia
is the primary cause unless there are good reasons not to do so, and grade
appropriately. A score of 4 in an individual aspect of grading (e.g. GFR) constitutes
severe toxicity in that aspect.
Table 2 Renal function at the baseline study
Mean (s.d.) Range Number(%) Reference
of abnormal results range
Glomerular function
GFR (ml min-' 1.73 m-2) 87.2 (31.5) 18-151 18/31 (58) 87-174
Proximal nephron function
Serum magnesium (mmol 1-') 0.75 (0.12) 0.44-0.95 10/35 (29) 0.70-1.00a
Serum sodium (mmol I-1) 139.2 (2.6) 134-147 9/35 (26) 137-144
Serum calcium (mmol 1-) 2.44 (0.12) 2.12-2.69 5/35 (14) 2.30-2.63
Serum chloride (mmol 1-') 105.5 (3.6) 95-110 2.35 (6) 100-109
Urine 52-M (mg mmol creatinine-1) 0.16 (0.38) 0.006-1.30 10/11 (91) <0.01
FEglucose (%) 0.2 (0.3) 0.0-1.5 18/25 (72) <0.05
Urine RBP (.g mmol creatine-1) 1326 (2252) 7-6000 5/7 (71) <9.5_<37.7a
FE magnesium (%) 4.6 (3.1) 1.1-11.2 2129 (7) 1.1-9.1
Distal nephron function
EMUpH 5.9 (0.9) 4.7-8.0 21/30b (70) <5.4
EMUO (mOsm kg-1)) 646 (215) 291-1064 13/29b (45) .600
General aspects
Urine NAG (U mmol creatinine-1) 0.98 (0.90) 0.08-3.72 22/30 (73) <0.34
Urine proteina(mg mmol creatine-1) 43.5 (80.5) 1.1-416.7 18/30 (60) <8.2-<19.3a
Urine AAP (U mmol creatinine-1) 5.63 (9.43) 0.00-47.14 15/27 (56) <1.7-<2.5a
s.d., standard deviation; FE, fractional excretion; EMUpH, early morning urine pH; EMUO, early morning urine osmolality. a Denotes
age-related reference range. bThe number of results not proven to be normal is indicated.
upon the indicators of nephrotoxicity. Only the cisplatin dose rate
was found to be significant. Therefore, unpaired t-tests and
Fisher's exact test were performed to compare the severity and
frequency of toxicity, as well as total cisplatin dose and the dura-
tion of other potentially nephrotoxic treatment, in the 'low' and
'high' dose rate groups. Changes with time were assessed by
paired t-tests.
RESULTS
Clinical consequences of nephrotoxicity
Cisplatin was discontinued early in two children who developed
acute renal failure after three courses of cisplatin. One required
peritoneal dialysis for a week. Both patients had other potential
risk factors, notably very recent or concurrent exposure to other
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Table 3 Cisplatin dose rate and nephrotoxicity
Measure of 'Low' dose rate 'High' dose rate P
nephrotoxicity (n = 21-23) (n = 10-12)
Total cisplatin dose (mg m-2) 587 (32) 532 (35) 0.28
Duration of other potentially nephrotoxic treatment (days) 40.5 (8.1) 26.1 (8.0) 0.26
GFR (ml min-' 1.73 m-2) 98.4 (5.4) 63.7 (10.0) 0.0025
Serum magnesium (mmol 1-') 0.79 (0.02) 0.66 (0.04) 0.0007
Nephrotoxicity score 0.71 (0.16) 2.40 (0.43) 0.0001
Results quoted as mean (standard error); 'Low' dose rate, 40 mg m-2 day-'; 'High' dose rate, >40-120 mg m-2 day-'.
potentially nephrotoxic drugs (aminoglycosides and amphotericin
B). Renal function improved in only one of these children; the
other patient and a further child (given five courses of cisplatin)
subsequently developed asymptomatic chronic renal failure (GFR
<30 ml min-' 1.73 m-2). The choice of subsequent chemotherapy
at the time of relapse was limited by the renal failure in the last
child. No patient developed tetany and none received long-term
oral magnesium supplementation after completion of treatment.
Renal function
The most important results (referring to the baseline study only)
are summarized below (Table 2). Inadequate blood or urine
samples (too small to permit biochemical analysis) and
unsuccessful GFR measurements (failure to achieve complete
intravenous injection of the radioisotope) were considered
inevaluable.
Glomerular function
Although GFR was low (range 18-86 ml min-' 1.73 m-2) in 18
(58%) of 31 evaluable children, the serum creatinine concentra-
tion was elevated in only seven of these. The two children with
low GFRs before cisplatin treatment did not demonstrate notice-
able glomerular toxicity - the GFR increased from 72 (pre-
cisplatin) to 79 ml min-1 1.73 m-2 (1 year post treatment, GFR
inevaluable at the end of treatment study) in one, and fell from
81 (pre-cisplatin) to 74 ml min-' 1.73 m-2 (end of treatment),
before rising to 94 and 97 ml min-' 1.73 m-2 (1 and 2 years post
treatment) in the other.
Proximal tubular function
Ten (29%) children were hypomagnesaemic (serum magnesium
ranging from 0.44 to 0.67 mmol 1-1). The two children with low
GFRs before cisplatin had normal serum magnesium concentra-
tions on all occasions of study. The fractional excretion of magne-
sium was measured in nine of the ten hypomagnesaemic children,
being high in two and in the upper half ofthe reference range (i.e.
between 5.1% and 9.1%) in two. The serum concentrations of
sodium, chloride and calcium were decreased slightly in 26%, 6%
and 14%, respectively, of children. The fractional excretion of
glucose was increased in 18 (72%) of 25 evaluable children. The
plasma glucose concentration (n = 35) and the fractional excre-
tions of sodium (n = 21) and calcium (n = 28) were normal in all
evaluable children. No child had an abnormal serum concentration
or fractional excretion ofpotassium or phosphate, orTmp/GFR.
The urinary P2-M/creatinine and RBP/creatinine ratios were
elevated in 10 of l1, and in five of seven evaluable children
respectively.
Distal tubular function
The early morning urine pH was <5.4 in only 9 (30%) of30 evalu-
able children, and osmolality .600 mOsm kg-' in only 16 (55%) of
29. However, no child had polydipsia, polyuria or a reduced serum
bicarbonate concentration.
General aspects ofrenal function
The urine AAP/creatinine, NAG/creatinine and total protein/
creatinine ratios were elevated in 15 (56%) of27, 22 (73%) of30,
and 18 (60%) of30 evaluable children respectively. Systolic blood
pressure was elevated without other apparent cause in one patient.
Grading scores
One patient had severe (grade 4) glomerular toxicity, but no child
had grade 4 tubular toxicity. The mean (range) GFR score was
0.84 (0-4), serum magnesium score 0.40 (0-3), and overall
nephrotoxicity score 1.26 (0-5). The overall score was evaluable
in 31 children - no toxicity was seen in ten (32%) patients, but ten
had mild (i.e. nephrotoxicity score = 1), ten moderate (score =
2-3) and one (3%) severe toxicity (score .4).
Patient- and treatment-related risk factors
Multiple regression analysis demonstrated that only the cisplatin
dose rate exerted a significant (P < 0.05) effect on the measures of
nephrotoxicity evaluated in this study. Those children treated with
the 'low' cisplatin dose rate had higher GFRs and serum magne-
sium concentrations, and lower nephrotoxicity scores than those
treated with higher dose rates (all P < 0.005). There was no signif-
icant difference between the two groups in total cisplatin dose
received or the duration ofother potentially nephrotoxic treatment
(Table 3). Although total cisplatin dose did not have an indepen-
dent effect on toxicity, the only four children with serum magne-
sium concentrations <0.60 mmol 1-' had all received doses
>500 mg m-2. Only 3 of21 evaluable 'low' cisplatin dose rate, but
eight of ten 'high' dose rate patients, suffered moderate or severe
toxicity (nephrotoxicity score >2) (P = 0.0007).
Changes in the severity of nephrotoxicity with time
Using paired data, the GFR was significantly higher at the I-year
study than at the baseline study [mean 104.0 (standard error 9.9)
vs 92.3 (8.4) ml min-' 1.73 m-2, n = 13, P = 0.04], with a similar
but statistically insignificant trend at the 2-year study (P = 0.19)
(Figure 1). Although some individual children showed either
progression or partial recovery of tubular toxicity during the
interval from the baseline to the 2-year study, no statistically
significant changes were observed in the group as a whole.
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Figure 1 Changes in glomerular filtration rate (GFR) in individual patients
with time after completion of cisplatin treatment. The lower limit of normal is
shown
DISCUSSION
The results of this follow-up study confirm previous reports of the
frequency, nature and severity of cisplatin-induced glomerular and
proximal nephron nephrotoxicity in children, leading to clinically
important reductions in GFR and serum magnesium concentration
(Ettinger et al, 1981; Hayes et al, 1981; Womeret al, 1985; Goren et
al, 1986; Sheldon et al, 1987; Bianchetti et al, 1990; Brock et al,
1991). These adverse effects occurred despite the use of hyper-
hydration protocols, which appear to reduce the frequency and
severity of nephrotoxicity, rather than abolish it altogether
(Daugaard and Abildgaard, 1989). Although few children suffered
from clinically significant toxicity, acute and/or chronic renal
failure in 3 out of 35 patients led to considerable constraints in the
choice of further chemotherapy. Despite the frequency of chronic
hypomagnesaemia, there were no episodes of paraesthesia, tetany
or convulsions after completion oftreatment in this study, although
such complications are well documented (Bellin and Selim, 1988).
A total of58% ofevaluable children had a GFR below the lower
limit of the reference range, and 29% were hypomagnesaemic.
These two major features of cisplatin nephrotoxicity did not
appear to be necessarily associated in individual patients.
Although the only fourchildren with serum magnesium concentra-
tions <0.60 mmol l-1 were among the 22 who had received
>500 mg m-2 cisplatin, the dose rate at which cisplatin was given
in each course appeared to be the major risk factor for the develop-
ment oftoxicity. Patients who had received cisplatin at a 'low' rate
of 40 mg m-2 day-' suffered less severe and frequent glomerular
and proximal nephron toxicity than those who had received a
'higher' rate. Glomerular, but not tubular, toxicity appeared to be
partially reversible with time after completion ofcisplatin.
Ofnine hypomagnesaemic children, two had unequivocal hyper-
magnesuria, and two had a fractional excretion ofmagnesium in the
upper half of the reference range. This implies inappropriate
magnesuria due to proximal nephron damage, particularly in the
thick ascending limb of the loop of Henle, as the normal renal
response to hypomagnesaemia leads to a reduced fractional excre-
tion (Shils, 1969; Dirks, 1983; Suki and Rouse, 1991).
Evidence of impaired proximal nephron reabsorption of other
electrolytes and small molecules was observed, with glycosuria in
72% of children, mild hyponatraemia in 26% and hypocalcaemia
in 14%, as described previously (Lammers et al, 1984; Vassal et al,
1987). Hypocalciuria despite normal or slightly high plasma
calcium concentrations has been reported (Bianchetti et al, 1990),
occurring alone or with hypomagnesaemia and hypokalaemic
metabolic alkalosis, suggesting a distal nephron lesion. Of 28
evaluable children in this study, six had a fractional excretion of
calcium at the lower limit of the normal range. Two were also
hypomagnesaemic, but none were hypokalaemic or alkalotic.
The frequent occurrence of subclinical distal nephron toxicity
was suggested by the failure to achieve adequate urine pH or
osmolality in the majority of children, but these abnormalities are
relatively non-specific. Dynamic functional investigations such as
acid loading and fluid deprivation studies were not performed
because of their unpleasant or potentially dangerous nature
(Skinner et al, 1991). However, no child had acidaemia or symp-
toms suggesting significant impairment of urinary concentration.
Clearer evidence of subclinical tubular damage was provided by
the frequency of raised urinary loss of low-molecular-weight
proteins and of renal tubular enzymes.
It is not clear why only some patients receiving cisplatin
develop severe glomerular impairment. Considerable interindi-
vidual differences in toxicity were apparent in this study, even
between patients of similar age and receiving similar administra-
tion schedules and total doses of cisplatin. It is possible that
interindividual variability in cisplatin pharmacokinetics may be at
least partly responsible (Reece et al, 1987).
This study evaluated the importance ofthe dose rate ofadminis-
tration of cisplatin during treatment courses, quantified in mg m-2
day-' of cisplatin treatment (for example during a 5-day cisplatin
course). This is not 'dose intensity', which is generally measured
per day of overall treatment duration (for example 18 weeks). The
greater nephrotoxicity of higher dose rates of cisplatin has not
been documented clearly before in children but is unsurprising as
it is generally considered that the renal toxicity of cisplatin is
reduced by prolonged infusion. The results of this study suggest
that cisplatin dose rates of 40 mg m-2 day-l should be used in pref-
erence to higher dose rates in children. The lack of a clear correla-
tion between total cisplatin dose and the severity ofnephrotoxicity
is consistent with other detailed long-term follow-up studies in
children (Womer et al, 1985; Sheldon et al, 1987; Brock et al,
1991), but contrasts with some earlier studies (Pratt et al, 1981;
Sexauer et al, 1985; Goren et al, 1986). It is possible that children
receiving higher total doses are at greater risk of significant toxi-
city, but that this effect is obscured by interindividual variability in
susceptibility. Similarly, the lack of obvious influence of other
potentially nephrotoxic treatment is in agreement with most
previous reports (Womer et al, 1985; Sheldon et al, 1987; Brock
et al, 1991), although effects in individual children can not be
excluded, and may have contributed to the occurrence of acute
renal failure in two children in this study.
The apparent partial reversibility in glomerular impairment over
the period of study is consistent with the observation of Brock
(Brock et al, 1991), and is an important finding in view of the
continued use of cisplatin in many combination chemotherapy
protocols in children. Although 12 of the baseline studies were
performed later than 3 months post-cisplatin, only six of these
were included in the comparison ofresults from the baseline study
with those from the 1-year study, with an interval between the
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baseline and 1-year study ranging from 5 to 8 months. This shorter
period of follow-up is unlikely to have led to a misleading result,
except perhaps by reducing the likelihood ofobserving any change
in toxicity with time after treatment. Further investigations are
continuing in a larger cohort of patients to enable clarification of
the outcome up to 10 years after treatment. Although the long-term
implications of chronic cisplatin-induced renal damage are
unknown, the possibility that they may include hypertension or
chronic renal failure is worrying.
In conclusion, this study has demonstrated the frequency of
clinically important glomerular and proximal nephron damage in
children treated with cisplatin, and has provided preliminary
evidence that such toxicity is more severe in children receiving
cisplatin dose rates greater than 40 mg m-2 day-'. Although both
drugs cause glomerular damage, the nature oftubular damage after
cisplatin is clearly distinct from that caused by ifosfamide
(Skinner et al, 1993). There was no evidence of further deteriora-
tion in renal function after completion of cisplatin treatment, but
the potential future implications for renal function in long-term
survivors are a cause of concern.
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